The effect of Metolazone and Hydrochlorothiazide in refractory edema

Comparing the impact of Metolazone plus Furosemide versus Hydrochlorthiazide Plus Furosemide in Patients with Heart failure and refractory edema: A Randomized clinical trial.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20111206008307N35

Enrollment

Registered

2020-07-25

Start date

2019-11-26

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systolic and diastolic heart failure. Combined systolic (congestive) and diastolic (congestive) heart failure

Interventions

Intervention 1: Intervention group: Will receive furosemide with Metolazone one 2.5 mg tablet daily, product of Teofarma Pharmaceutical Company, until improving clinical symptoms. Intervention 2: Con

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with diastolic heart failure and refractory edema Glomerular l filtration rate (GFR) > 30

Exclusion criteria

Exclusion criteria: Renal dysfunction (creatinine clearance <30 ml/min) History of end-stage renal failure or dialysis Acute myocardial infarction Cardiogenic shock Contraindications for metolazone and hydrochlorothiazide Hypoalbuminemia Patients who are not satisfied

Design outcomes

Primary

Measure	Time frame
Fluid Input/Output. Timepoint: Daily. Method of measurement: Urine bag.;Sodium (Na). Timepoint: Daily. Method of measurement: Laboratory test.;Edema. Timepoint: Daily. Method of measurement: Physical examination.;Potassium (K). Timepoint: Daily. Method of measurement: Laboratory test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Taher Entezari-maleki

Tabriz University of Medical Sciences

tentezari@gmail.com+98 41 3335 5983

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026